Patents by Inventor Tsutomu Satoh

Tsutomu Satoh has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11031597
    Abstract: A negative electrode material for a lithium-ion secondary battery contains graphitic particles of which a standard deviation of circularity at a cumulative frequency ranging from 10% by particle to 90% by particle from the lower circularity, determined by a flow-type particle analyzer, is from 0.05 to 0.1.
    Type: Grant
    Filed: January 4, 2018
    Date of Patent: June 8, 2021
    Assignee: SHOWA DENKO MATERIALS CO., LTD.
    Inventors: Kento Hoshi, Hideyuki Tsuchiya, Tsutomu Satoh
  • Publication number: 20210135220
    Abstract: An anode material for a lithium ion secondary battery including a carbon material satisfying the following (1) to (3), (6), and (7): (1) an average particle size (D50) is 22 ?m or less, (2) D90/D10 of particle sizes is 2.2 or less, (3) a linseed oil absorption amount is 50 mL/100 g or less, (6) a portion of the carbon material with a sphericity of from 0.6 to 0.8 and a particle size of from 10 ?m to 20 ?m is 5% by number or more, and (7) a portion of the carbon material with the sphericity of 0.7 or less and a particle size of 10 ?m or less is 0.3% by number or less.
    Type: Application
    Filed: January 29, 2018
    Publication date: May 6, 2021
    Inventors: Motohiro ISAKA, Hideyuki TSUCHIYA, Kento HOSHI, Tsutomu SATOH, Keita SUGA
  • Publication number: 20210095053
    Abstract: The present invention provides alginic acid derivatives represented by formula (I) and formula (II), and a novel crosslinked alginic acid obtained by carrying out a Huisgen reaction using an alginic acid derivative of formula (I) and an alginic acid derivative of formula (II). There are thereby provided novel alginic acid derivatives and a novel crosslinked alginic acid.
    Type: Application
    Filed: December 11, 2020
    Publication date: April 1, 2021
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Shoji FURUSAKO, Tomohiro NARUMI, Tsutomu SATOH
  • Publication number: 20210024659
    Abstract: The present invention provides alginic acid derivatives having a group represented by general formula (I) or general formula (II) (the right side of the dashed line is excluded in each formula) at a portion of the carboxyl groups in an alginic acid. Novel alginic acid derivatives are thereby provided.
    Type: Application
    Filed: March 27, 2019
    Publication date: January 28, 2021
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Shoji FURUSAKO, Tsutomu SATOH, Tomohiro NARUMI
  • Publication number: 20200308136
    Abstract: Provided are type I, III, V and VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyridin-3-yl)urea which are useful as bulk pharmaceutical crystals. Also provided are type I, III, V and VI crystals of 1-((1R,2R)-2-hydroxy-4,4-dimethyl-1,2,3,4-tetrahydronaphthalen-1-yl)-3-(5-methyl-6-(2-methylpyrimidin-5-yl)-2-phenylpyridin-3-yl)urea having excellent TrkA inhibitory effect, medicines and medicinal composition containing these crystals, and a method for producing these crystals.
    Type: Application
    Filed: September 13, 2018
    Publication date: October 1, 2020
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Yuji KAWADA, Fumihiko SAITOH, Hiroshi NAGASUE, Tsutomu SATOH
  • Publication number: 20190348679
    Abstract: A negative electrode material for a lithium-ion secondary battery contains graphitic particles of which a standard deviation of circularity at a cumulative frequency ranging from 10% by particle to 90% by particle from the lower circularity, determined by a flow-type particle analyzer, is from 0.05 to 0.1.
    Type: Application
    Filed: January 4, 2018
    Publication date: November 14, 2019
    Inventors: Kento HOSHI, Hideyuki TSUCHIYA, Tsutomu SATOH
  • Publication number: 20190097218
    Abstract: Provided is an anode material for a lithium ion secondary battery, which the anode material satisfies at least one of the following (1) or (2). (1) The anode material includes: a first carbon material as a core; and a second carbon material present on at least a part of a surface of the first carbon material, and having a crystallinity lower than the crystallinity of the first carbon material; and the anode material has at least two peaks within the range of from 395 eV to 405 eV in an X-ray photoelectron spectrum thereof. (2) The anode material has an R value of from 0.1 to 1.0, and has at least two peaks within the range of from 395 eV to 405 eV in an X-ray photoelectron spectrum thereof.
    Type: Application
    Filed: April 28, 2017
    Publication date: March 28, 2019
    Inventors: Tsutomu SATOH, Hideyuki TSUCHIYA, Motohiro ISAKA, Kento HOSHI, Keita SUGA, Yoshinori UCHIYAMA
  • Publication number: 20190071441
    Abstract: The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided are a method for manufacturing a 4-heteroaryl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; and an intermediate for this manufacturing method.
    Type: Application
    Filed: November 6, 2018
    Publication date: March 7, 2019
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Tsutomu SATOH, Takashi KUDOH, Tetsuo IWAMA
  • Patent number: 10208010
    Abstract: The present invention provides a type I crystal of (E)-2-(7-trifluoromethyl-chroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide having excellent TRPV1 antagonistic activity, a drug and a pharmaceutical composition containing this crystal, and a method for producing the crystal. The present invention provides a type I crystal of (E)-2-(7-trifluoromethyl-chroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide that is excellent in at least one feature selected from the group consisting of storage stability, photostability and thermodynamic stability, that can be preferably obtained with industrially high reproducibility, yield and purity, and that is useful as a crystal of an active pharmaceutical ingredient.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: February 19, 2019
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventor: Tsutomu Satoh
  • Patent number: 10174025
    Abstract: The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided are a method for manufacturing a 4-heteroaryl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; and an intermediate for this manufacturing method.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: January 8, 2019
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Tsutomu Satoh, Takashi Kudoh, Tetsuo Iwama
  • Publication number: 20180346436
    Abstract: The present invention provides a type I crystal of (E)-2-(7-trifluoromethyl-chroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide having excellent TRPV1 antagonistic activity, a drug and a pharmaceutical composition containing this crystal, and a method for producing the crystal. The present invention provides a type I crystal of (E)-2-(7-trifluoromethyl-chroman-4-ylidene)-N-((7R)-7-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl)acetamide that is excellent in at least one feature selected from the group consisting of storage stability, photostability and thermodynamic stability, that can be preferably obtained with industrially high reproducibility, yield and purity, and that is useful as a crystal of an active pharmaceutical ingredient.
    Type: Application
    Filed: May 30, 2018
    Publication date: December 6, 2018
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventor: Tsutomu SATOH
  • Publication number: 20180099964
    Abstract: The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided are a method for manufacturing a 4-heteroaryl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; and an intermediate for this manufacturing method.
    Type: Application
    Filed: December 13, 2017
    Publication date: April 12, 2018
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Tsutomu SATOH, Takashi KUDOH, Tetsuo IWAMA
  • Patent number: 9902723
    Abstract: The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided is a method for manufacturing a 4-substituted-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; or an intermediate for this manufacturing method.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: February 27, 2018
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Tsutomu Satoh, Takashi Kudoh, Tetsuo Iwama
  • Patent number: 9879009
    Abstract: The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided are a method for manufacturing a 4-heteroaryl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; and an intermediate for this manufacturing method.
    Type: Grant
    Filed: July 29, 2015
    Date of Patent: January 30, 2018
    Assignee: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Tsutomu Satoh, Takashi Kudoh, Tetsuo Iwama
  • Publication number: 20170217958
    Abstract: The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided are a method for manufacturing a 4-heteroaryl-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; and an intermediate for this manufacturing method.
    Type: Application
    Filed: July 29, 2015
    Publication date: August 3, 2017
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Tsutomu SATOH, Takashi KUDOH, Tetsuo IWAMA
  • Publication number: 20170210740
    Abstract: The present invention provides a method for manufacturing a compound represented by formula (I). With this method, provided is a method for manufacturing a 4-substituted-N-(2-phenyl-[1,2,4]triazolo[1,5-a]pyridin-7-yl)-1H-pyrazole-5-carboxylic acid amide derivative; or an intermediate for this manufacturing method.
    Type: Application
    Filed: July 29, 2015
    Publication date: July 27, 2017
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Tsutomu SATOH, Takashi KUDOH, Tetsuo IWAMA
  • Publication number: 20130107536
    Abstract: An adapter is hooked to a ceiling socket located on the ceiling. Any one of first ring material and second ring material fixed to a chassis is interlocked to the adapter, to install the lighting apparatus on the ceiling. A circuit board is connected to a sensor board on which an illuminance sensor is mounted. The illuminance sensor outputs electric signals corresponding to the detected illuminance. A control unit adjusts the brightness of light emitted from a LED module, on the basis of the illuminance detected by the illuminance sensor. The illuminance sensor is fixed to the chassis in such a manner that it is inclined from a rotation axis about which the chassis is rotated.
    Type: Application
    Filed: June 16, 2011
    Publication date: May 2, 2013
    Applicant: SHARP KABUSHIKI KAISHA
    Inventors: Jun Hiraoka, Ken Ueda, Tsutomu Satoh
  • Patent number: 8383839
    Abstract: A compound represented by formula (I?): (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; R1 represents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group, an NO2 group, or the like; R2 represents halogen, amino, a hydrocarbon group, an aromatic heterocyclic group, or an oxo group; X1 represents O, —NR3—, or —S(O)r-; X2 represents a methylene group, O, —NR3—, or —S(O)r-; Q? represents a heteroaryl group, a heteroarylalkyl group, a substituted aryl group, or an aralkyl group; Cycle moiety represents an aryl ring or a heteroaryl ring; and the wavy line represents an E-isomer or a Z-isomer), a salt of the compound, or a solvate of the compound or the salt. A pharmaceutical composition and a transient receptor potential type I (TRPV1) receptor antagonist each contain, as an active ingredient, at least one of the compound, a salt of the compound, and a solvate of the compound or the salt.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: February 26, 2013
    Assignee: Mochida Pharmaceutical Co., Ltd.
    Inventors: Hideharu Uchida, Naoto Kosuga, Tsutomu Satoh, Daido Hotta, Tomoyuki Kamino, Yoshitaka Maeda, Ken-ichi Amano, Yasushige Akada
  • Publication number: 20130003369
    Abstract: A lighting apparatus includes a LED module provided at the central side of a chassis and a reflection sheet reflecting light emitted from the LED module. The LED module emits light to the outer edge portion of the chassis and then the light is reflected on the reflection sheet to perform illumination so that glare can be reduced. Then, the light emitted from the LED module is reflected on the reflection sheet in many directions so that a substantially uniform illuminated light with less illumination unevenness can be achieved. The LED module is not arranged at the outer edge portion of the chassis so that moment acting on the chassis can be reduced. Therefore, the deformation of chassis can be prevented.
    Type: Application
    Filed: March 4, 2011
    Publication date: January 3, 2013
    Inventors: Jun Hiraoka, Ken Ueda, Tsutomu Satoh, Masanori Morigami
  • Publication number: 20110112071
    Abstract: A compound represented by formula (I?): (wherein m, n, and p each represent 0 to 2; q represents 0 or 1; R1 represents halogen, a hydrocarbon group, a heterocyclic group, an alkoxy group, an alkoxycarbonyl group, a sulfamoyl group, a CN group, an NO2 group, or the like; R2 represents halogen, amino, a hydrocarbon group, an aromatic heterocyclic group, or an oxo group; X1 represents O, —NR3—, or —S(O)r-; X2 represents a methylene group, O, —NR3—, or —S(O)r-; Q? represents a heteroaryl group, a heteroarylalkyl group, a substituted aryl group, or an aralkyl group; Cycle moiety represents an aryl ring or a heteroaryl ring; and the wavy line represents an E-isomer or a Z-isomer), a salt of the compound, or a solvate of the compound or the salt. A pharmaceutical composition and a transient receptor potential type I (TRPV1) receptor antagonist each contain, as an active ingredient, at least one of the compound, a salt of the compound, and a solvate of the compound or the salt.
    Type: Application
    Filed: January 18, 2011
    Publication date: May 12, 2011
    Applicant: MOCHIDA PHARMACEUTICAL CO., LTD.
    Inventors: Hideharu UCHIDA, Naoto Kosuga, Tsutomu Satoh, Daido Hotta, Tomoyuki Kamino, Yoshitaka Maeda, Ken-ichi Amano, Yasushige Akada